Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SNY
stocks logo

SNY

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2028Q3
FY2028Q4
FY2029Q1
10.00B
-6.97%
0.955
+0.4%
12.98B
-3.44%
0.919
-2.08%
11.54B
+9.21%
1.713
+10.87%
Estimates Revision
The market is revising Downward the revenue expectations for Sanofi (SNY) for FY2025, with the revenue forecasts being adjusted by -4.12% over the past three months. During the same period, the stock price has changed by -4.21%.
Revenue Estimates for FY2025
Revise Downward
down Image
-4.12%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-50.18%
In Past 3 Month
Stock Price
Go Down
down Image
-4.21%
In Past 3 Month
3 Analyst Rating
up Image0
Wall Street analysts forecast SNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNY is 64.00 USD with a low forecast of 63.00 USD and a high forecast of 65.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
2 Hold
0 Sell
Moderate Buy
up Image0
Current: 51.680
sliders
Low
63.00
Averages
64.00
High
65.00
up Image0
Current: 51.680
sliders
Low
63.00
Averages
64.00
High
65.00
Goldman Sachs
James Quigley
Hold
Initiates
$65
2025-03-21
Reason
Goldman Sachs
James Quigley
Price Target
$65
2025-03-21
Initiates
Hold
Reason
Goldman Sachs initiated coverage of Sanofi with a Neutral rating and $65 price target. While the firm sees Sanofi emerging as a pipeline story, it believes this is somewhat reflected at current levels, with additional proof points required before Sanofi can be considered an "R&D leader," the analyst tells investors.
Argus Research
Jasper Hellweg
Strong Buy
Maintains
$55 → $60
2024-07-26
Reason
Argus Research
Jasper Hellweg
Price Target
$55 → $60
2024-07-26
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Sanofi SA (SNY.O) is 10.86, compared to its 5-year average forward P/E of 11.13. For a more detailed relative valuation and DCF analysis to assess Sanofi SA 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
11.13
Current PE
10.86
Overvalued PE
13.75
Undervalued PE
8.51

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average EV/EBITDA
9.33
Current EV/EBITDA
8.29
Overvalued EV/EBITDA
10.01
Undervalued EV/EBITDA
8.64

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PS
2.65
Current PS
2.35
Overvalued PS
2.87
Undervalued PS
2.43

Financials

Annual
Quarterly

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

SNY News & Events

Events Timeline

(ET)
2025-05-15
18:18:07
Sanofi treatment of sickle cell disease granted FDA orphan status
select
link
2025-05-14 (ET)
2025-05-14
12:32:59
Sanofi to invest at least $20B in U.S. through 2030
select
2025-05-14
06:29:46
U.S. biotech companies debate relocating trials outside U.S., Reuters reports
select
link
Sign Up For More Events
Sign Up For More Events

News

Preview
8.5
05-14SeekingAlpha
PinnedSanofi will invest at least $20B in the U.S., focus on R&D spends

  • Sanofi's Investment Plans: Sanofi will invest at least $20 billion in the U.S. by 2030, focusing on research and manufacturing, amid a trend of similar investments from other pharmaceutical companies due to tariff threats.

  • Expansion of Manufacturing and R&D: The investment will significantly increase spending on research and development in the U.S. and expand manufacturing capacity through direct investments and partnerships with domestic manufacturers.

Preview
4.5
05-15Benzinga
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030

  • Sanofi's Investment Plans: Sanofi SA announced a commitment to invest at least $20 billion in the U.S. by 2030, focusing on research, development, and manufacturing, which is expected to create jobs and enhance the U.S. supply chain.

  • Industry-Wide Manufacturing Investments: Other pharmaceutical companies, including Eli Lilly, Thermo Fisher, and Johnson & Johnson, are also increasing their investments in U.S. manufacturing amid tariff uncertainties and government initiatives to boost domestic production.

Preview
4.5
05-15Newsfilter
Sanofi to invest at least $20 billion in the US through 2030, growing investments in science and expanding domestic manufacturing

  • Sanofi's Investment Plans: Sanofi plans to invest at least $20 billion in the United States by 2030, focusing on increasing research and development spending and expanding US manufacturing capabilities.

  • Impact on Jobs and Innovation: The investment is expected to create high-paying jobs and contribute to innovation and supply chain enhancement in various communities across the US.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Sanofi SA (SNY) stock price today?

The current price of SNY is 51.68 USD — it has increased 1.61 % in the last trading day.

arrow icon

What is Sanofi SA (SNY)'s business?

Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.

arrow icon

What is the price predicton of SNY Stock?

Wall Street analysts forecast SNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNY is 64.00 USD with a low forecast of 63.00 USD and a high forecast of 65.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Sanofi SA (SNY)'s revenue for the last quarter?

Sanofi SA revenue for the last quarter amounts to NaN USD, decreased % YoY.

arrow icon

What is Sanofi SA (SNY)'s earnings per share (EPS) for the last quarter?

Sanofi SA. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Sanofi SA (SNY)'s fundamentals?

The market is revising Downward the revenue expectations for Sanofi (SNY) for FY2025, with the revenue forecasts being adjusted by -4.12% over the past three months. During the same period, the stock price has changed by -4.21%.
arrow icon

How many employees does Sanofi SA (SNY). have?

Sanofi SA (SNY) has 87994 emplpoyees as of May 17 2025.

arrow icon

What is Sanofi SA (SNY) market cap?

Today SNY has the market capitalization of 130.46B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free